Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Xin Hua Du Industrial Group is a prominent Chinese private conglomerate founded by billionaire entrepreneur Chen Fashu in 1989. While originally focused on retail and mining, the group has become a major force in the life sciences and healthcare sectors through its significant ownership stake in Yunnan Baiyao Group, one of China's most iconic pharmaceutical companies. The group operates primarily as an investment holding entity, managing a diverse portfolio that includes traditional Chinese medicine (TCM), consumer healthcare, and medical research investments. Xin Hua Du is recognized for its strategic role in the modernization and market expansion of Chinese healthcare brands. Its influence in the industry is exercised through capital allocation and corporate governance within its subsidiary and affiliate networks, particularly in the integration of TCM with modern pharmaceutical standards.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Xin Hua Du Industrial Group.